WAKIX Demonstrated Efficacy and Safety in Clinical Studies in Adult and Pediatric Patients

WAKIX was evaluated in adult and pediatric patients with narcolepsy type 1 and narcolepsy type 2

Learn more about the clinical study results for WAKIX in both excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy, and EDS in pediatric patients 6 years of age and older with narcolepsy, and view the WAKIX safety profile from clinical studies.